The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol.
Kristien E C BouterErik J M van BommelHans JansenDewi van HarskampHenk SchierbeekMariëtte T AckermansMireille J SerlieAlinda W M SchimmelMax NieuwdorpGeesje M Dallinga-ThieDaniël H van RaaltePublished in: Diabetes, obesity & metabolism (2020)
Dapagliflozin has no effect on plasma LDL-cholesterol levels or VLDL-apoB fluxes in the context of optimal lipid-lowering treatment, which will thus not limit cardiovascular benefit when lipids are adequately controlled.